Evotec Announces Progress in Preclinical Neuroscience Partnership with Bristol Myers Squibb

Evotec Announces Progress in Preclinical Neuroscience Partnership with Bristol Myers Squibb

Advances made in preclinical pipeline addressing neurodegenerative diseasesEvotec receives US$ 25 m payment to support continued progression of joint programs

Evotec and Bristol Myers Squibb Advance Preclinical Pipeline for Neurodegenerative Diseases

Evotec SE has announced notable progress in its strategic neuroscience partnership with Bristol Myers Squibb, highlighted by a US$ 25 million milestone payment for advancements in their joint preclinical pipeline targeting neurodegenerative diseases. Launched in 2016 and extended in 2023, the collaboration aims to discover and develop disease-modifying therapies for conditions with limited treatment options. Key programs include EVT8683 (BMS-986…

Evotec and Bristol Myers Squibb advance neuroscience partnership

$25m milestone payment supports pipeline progress in neurodegenerative disease research

Evotec Receives US$ 25 Million Milestone Payment from Bristol Myers Squibb for Progress in Neurodegenerative Disease Partnership

Open the article to view the coverage from EuropaWire.eu

Evotec (NASDAQ: EVO) advances preclinical BMS neuroscience programs, receives $25M

Evotec gets US$ 25 m from Bristol Myers Squibb for progress in a neuroscience partnership. Extended 8 years in 2023; EVT8683/BMS‑986419 completed Phase 1.